1-Month Results From a Prospective Experience on CAS Using CGuard Stent System

Sirignano, Pasqualino; Stabile, Eugenio; Mansour, Wassim; Capoccia, Laura; Faccenna, Federico; Intrieri, Francesco; Ferri, Michelangelo; Saccà, Salvatore; Sponza, Massimo; Mortola, Paolo; Ronchey, Silvia; Grillo, Placido; Chiappa, Roberto; Losa, Sergio; Setacci, Francesco; Pirrelli, Stefano; Taurino, Maurizio; Ruffino, Maria Antonella; Udini, M; Palombo, Domenico; Ippoliti, Arnaldo; Montelione, Nunzio; Setacci, Carlo; Donato, Gianmarco de; Ruggeri, Massimo; Speziale, Francesco

doi:10.1016/j.jcin.2020.05.026

Cited by 17 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IRONGUARD-2 study population (733 consecutive patents) had a larger proportion of DM patients (36%). Peri-and postprocedural adverse clinical outcomes (cumulative 30-day death/stroke/MI rate of 1.2%) showed no difference between DM and non-DM patients [10]; this corroborates the present findings in our study. Also 12-month data IRONGUARD-2 showed no difference in death/stroke/MI between DM vs. non-DM patients.…”

Section: Journal Of Diabetes Researchsupporting

confidence: 93%

“…There were 6 incidences of ISR; however, no DM status was provided for these patients [44]. Overall, the IRONGUARD-1 [42,43] and IRONGUARD-2 [10,44] clinical results are in concordance with our present findings.…”

Section: Journal Of Diabetes Researchsupporting

confidence: 90%

“…It is unclear, however, whether the affected patients were diabetic or nondiabetic, and evaluation of any potential impact of DM on ISR in dual-metallic layer stents is warranted. Regarding MCS, two large-scale Italian registries have been recently published: IRONGUARD-1 [ 42 , 43 ] and IRONGUARD-2 [ 10 , 44 ]. The IRONGUARD-1 study population of 200 patients included 28% diabetics.…”

Section: Discussionmentioning

confidence: 99%

“…Recent evidence indicates that, in the coronaries, the adverse impact of diabetes on postprocedural complications may be offset by using new-generation drug-eluting stents [ 7 ]. In CAS, MicroNet-covered stents (MCS) have been recently shown to effectively prevent periprocedural and long-term lesion-related cerebral embolism [ 8 ], and they may reduce clinical complications of CAS [ 9 , 10 ], presenting a major improvement in the endovascular armentarium [ 11 ]. MCS outcomes in the diabetic population have not been evaluated.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diabetes Mellitus and Clinical Outcomes in Carotid Artery Revascularization Using Second-Generation, MicroNet-Covered Stents: Analysis from the PARADIGM Study

Mazurek

Borratyńska

Gancarczyk

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

Introduction. Carotid artery stenting (CAS) using conventional (single-layer) stents is associated with worse clinical outcomes in diabetes mellitus (DM) vs. non-DM patients: an effect driven largely by lesion-related adverse events. CAS outcomes with MicroNet-covered stents (MCS) in diabetic patients have not been evaluated. Aim. To compare short- and long-term clinical outcomes and restenosis rate in DM vs. non-DM patients with carotid stenosis treated using MCS. Materials and Methods. In a prospective study in all-comer symptomatic and increased-stroke-risk asymptomatic carotid stenosis, 101 consecutive patients (age 51-86 years, 41% diabetics) underwent 106 MCS-CAS. Clinical outcomes and duplex ultrasound velocities were assessed periprocedurally and at 30 days/12 months. Results. Baseline characteristics of DM vs. non-DM patients were similar except for a higher prevalence of recent cerebral symptoms in DM. Type 1 and type 1+2 plaques were more prevalent in DM patients (26.7% vs. 9.8%, p = 0.02 ; 62.2% vs. 37.7%, p = 0.01 ). Proximal embolic protection was more prevalent in DM (60% vs. 36%; p = 0.015 ). 30-day clinical complications were limited to a single periprocedural minor stroke in DM (2.4% vs. 0%, p = 0.22 ). 12-month in-stent velocities and clinical outcomes were not different (death rate 4.8% vs. 3.3%; p = 0.69 ; no new strokes). Restenosis rate was not different (0% vs. 1.7%, p = 0.22 ). Conclusions. MCS may offset the adverse impact of DM on periprocedural, 30-day, and 12-month clinical complications of CAS and minimize the risk of in-stent restenosis. In this increased-stroke-risk cohort, adverse event rate was low both in DM and non-DM. Further larger-scale clinical datasets including extended follow-ups are warranted.

show abstract

Section: Journal Of Diabetes Researchsupporting

confidence: 93%

Section: Journal Of Diabetes Researchsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diabetes Mellitus and Clinical Outcomes in Carotid Artery Revascularization Using Second-Generation, MicroNet-Covered Stents: Analysis from the PARADIGM Study

Mazurek

Borratyńska

Gancarczyk

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…In 103 patients recently treated with CGuard, no DSM occurred by 30 days [ 230 ]. A very recent 733-patient multicentric (20 centers) CGuard study in Italy showed three strokes by 30 days (0.4%, cumulative DSM rate of 0.95%) [ 231 ] and a 12-month ISR rate of 0.82% [ 232 ]. These outcomes are consistent with those indicated by the meta-analytic model ( Table 2 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes of Second- versus First-Generation Carotid Stents: A Systematic Review and Meta-Analysis

Mazurek

Malinowski

Rosenfield

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: Single-cohort studies suggest that second-generation stents (SGS; “mesh stents”) may improve carotid artery stenting (CAS) outcomes by limiting peri- and postprocedural cerebral embolism. SGS differ in the stent frame construction, mesh material, and design, as well as in mesh-to-frame position (inside/outside). Objectives: To compare clinical outcomes of SGS in relation to first-generation stents (FGSs; single-layer) in CAS. Methods: We performed a systematic review and meta-analysis of clinical studies with FGSs and SGS (PRISMA methodology, 3302 records). Endpoints were 30-day death, stroke, myocardial infarction (DSM), and 12-month ipsilateral stroke (IS) and restenosis (ISR). A random-effect model was applied. Results: Data of 68,422 patients from 112 eligible studies (68.2% men, 44.9% symptomatic) were meta-analyzed. Thirty-day DSM was 1.30% vs. 4.11% (p < 0.01, data for SGS vs. FGS). Among SGS, both Casper/Roadsaver and CGuard reduced 30-day DSM (by 2.78 and 3.03 absolute percent, p = 0.02 and p < 0.001), whereas the Gore stent was neutral. SGSs significantly improved outcomes compared with closed-cell FGS (30-day stroke 0.6% vs. 2.32%, p = 0.014; DSM 1.3% vs. 3.15%, p < 0.01). At 12 months, in relation to FGS, Casper/Roadsaver reduced IS (−3.25%, p < 0.05) but increased ISR (+3.19%, p = 0.04), CGuard showed a reduction in both IS and ISR (−3.13%, −3.63%; p = 0.01, p < 0.01), whereas the Gore stent was neutral. Conclusions: Pooled SGS use was associated with improved short- and long-term clinical results of CAS. Individual SGS types, however, differed significantly in their outcomes, indicating a lack of a “mesh stent” class effect. Findings from this meta-analysis may provide clinically relevant information in anticipation of large-scale randomized trials.

show abstract